12 weeks between Pfizer jabs increases Covid immune response in elderly
The UK s approach to vaccine rollout appears to be more effective than separating doses by three weeks
A phial of Pfizer-BioNTech Covid-19 vaccine (Image: Getty)
Never miss another Nottinghamshire story by signing up to our free email updatesInvalid EmailSomething went wrong, please try again later.
Subscribe
When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice
A 12-week gap between Pfizer coronavirus vaccine doses significantly increases the immune response in older people, a new study suggests.
Over-80s show similar antibody responses following single vaccination with either Pfizer or AstraZeneca vaccine but cellular responses are enhanced after AstraZeneca vaccine pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.
The Pfizer vaccine produces an “off the scale” immune response that is likely to protect against the Brazilian variant of Covid-19, researchers say.
The biggest study on antibody and cellular immune factors to date suggests people are likely to be protected against the Wuhan, Kent and Brazilian types of coronavirus following two doses of the vaccine.
The research, led by the University of Birmingham and including Public Health England’s Porton Down laboratory, found 98% of people aged 80 or over who had two doses of the Pfizer jab had a strong antibody immune response.
It comes as other new data from Pfizer suggests the vaccine is 100% effective in preventing Covid-19 cases in South Africa, where the variant which emerged in that country is common.
The Pfizer Covid-19 vaccine appears to offer 100% protection against the South African variant and most likely protects against the Brazilian variant, according to two new studies.
Research published by Pfizer/BioNTech on Thursday offers the first in-human evidence of how the vaccine protects against the South African variant that has been worrying scientists.
The pharmaceutical giant said its findings show the vaccine is 100% effective in preventing Covid-19 cases in South Africa – where the South African variant is now common.
(PA Graphics)
Among 800 people in South Africa, nine cases of the South African variant of Covid were observed – all in the group not given the vaccine.